BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 31001905)

  • 1. EndoPredict versus uPA/PAI-1 in breast cancer: Comparison of markers and association with clinicopathological parameters.
    Jakubowicz E; Martin B; Hoffmann R; Kröncke T; Jung T; Steierl R; Steinfeld D; Schenkirsch G; Kriegsmann J; Märkl B
    Breast J; 2019 May; 25(3):450-454. PubMed ID: 31001905
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Decision impact and feasibility of different ASCO-recommended biomarkers in early breast cancer: Prospective comparison of molecular marker EndoPredict and protein marker uPA/PAI-1.
    Ettl J; Klein E; Hapfelmeier A; Grosse Lackmann K; Paepke S; Petry C; Specht K; Wolff L; Höfler H; Kiechle M
    PLoS One; 2017; 12(9):e0183917. PubMed ID: 28877230
    [TBL] [Abstract][Full Text] [Related]  

  • 3. European cost-effectiveness study of uPA/PAI-1 biomarkers to guide adjuvant chemotherapy decisions in breast cancer.
    Marguet S; Mazouni C; Ramaekers BL; Dunant A; Kates R; Jacobs VR; Joore MA; Harbeck N; Bonastre J
    Eur J Cancer; 2016 Aug; 63():168-79. PubMed ID: 27322916
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical relevance of invasion factors urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 for individualized therapy decisions in primary breast cancer is greatest when used in combination.
    Harbeck N; Kates RE; Schmitt M
    J Clin Oncol; 2002 Feb; 20(4):1000-7. PubMed ID: 11844823
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Her-2/neu and urokinase-type plasminogen activator and its inhibitor in breast cancer.
    Konecny G; Untch M; Arboleda J; Wilson C; Kahlert S; Boettcher B; Felber M; Beryt M; Lude S; Hepp H; Slamon D; Pegram M
    Clin Cancer Res; 2001 Aug; 7(8):2448-57. PubMed ID: 11489825
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Urokinase-type plasminogen activator and its inhibitor type 1 predict disease outcome and therapy response in primary breast cancer.
    Harbeck N; Kates RE; Schmitt M; Gauger K; Kiechle M; Janicke F; Thomassen C; Look MP; Foekens JA
    Clin Breast Cancer; 2004 Dec; 5(5):348-52. PubMed ID: 15585071
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Urokinase-type plasminogen activator and its inhibitor PAI-1: predictors of poor response to tamoxifen therapy in recurrent breast cancer.
    Foekens JA; Look MP; Peters HA; van Putten WL; Portengen H; Klijn JG
    J Natl Cancer Inst; 1995 May; 87(10):751-6. PubMed ID: 7563153
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis.
    Grøndahl-Hansen J; Christensen IJ; Rosenquist C; Brünner N; Mouridsen HT; Danø K; Blichert-Toft M
    Cancer Res; 1993 Jun; 53(11):2513-21. PubMed ID: 8388317
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Urokinase plasminogen activator and its inhibitor, PAI-1, as prognostic markers in breast cancer: from pilot to level 1 evidence studies.
    Duffy MJ
    Clin Chem; 2002 Aug; 48(8):1194-7. PubMed ID: 12142372
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of Ki67 and uPA/PAI-1 expression in intermediate-risk early stage breast cancers.
    Deluche E; Venat-Bouvet L; Leobon S; Fermeaux V; Mollard J; Saidi N; Jammet I; Aubard Y; Tubiana-Mathieu N
    BMC Cancer; 2017 Sep; 17(1):662. PubMed ID: 28954632
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of uPA, PAT-1, and uPAR in nipple aspirate fluid (NAF) with breast cancer.
    Qin W; Zhu W; Wagner-Mann C; Folk W; Sauter ER
    Cancer J; 2003; 9(4):293-301. PubMed ID: 12967140
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant chemotherapy in node-negative breast cancer: UPA/PAI-1 determinations for 163 cases.
    Vénat-Bouvet L; Fermeaux V; Leobon S; Saidi N; Monteil J; Mollard J; Aubard Y; Jammet I; Tubiana-Mathieu N
    Anticancer Res; 2014 Mar; 34(3):1213-7. PubMed ID: 24596362
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive impact of urokinase-type plasminogen activator: plasminogen activator inhibitor type-1 complex on the efficacy of adjuvant systemic therapy in primary breast cancer.
    Manders P; Tjan-Heijnen VC; Span PN; Grebenchtchikov N; Foekens JA; Beex LV; Sweep CG
    Cancer Res; 2004 Jan; 64(2):659-64. PubMed ID: 14744782
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424).
    Harbeck N; Kates RE; Look MP; Meijer-Van Gelder ME; Klijn JG; Krüger A; Kiechle M; Jänicke F; Schmitt M; Foekens JA
    Cancer Res; 2002 Aug; 62(16):4617-22. PubMed ID: 12183417
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasminogen activator inhibitor-1 as a measure of vascular remodelling in breast cancer.
    Fox SB; Taylor M; Grøndahl-Hansen J; Kakolyris S; Gatter KC; Harris AL
    J Pathol; 2001 Sep; 195(2):236-43. PubMed ID: 11592104
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [u-Plasminogen activator (urinary plasminogen activator, urokinase) (uPA) and its PA-1 type 1 inhibitor are not only prognostically but also predictively significant and support clinical decisions on therapy in primary carcinoma of the breast].
    Harbeck N; Thomssen C
    Zentralbl Gynakol; 2003 Sep; 125(9):362-7. PubMed ID: 14569518
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1.
    Jänicke F; Prechtl A; Thomssen C; Harbeck N; Meisner C; Untch M; Sweep CG; Selbmann HK; Graeff H; Schmitt M;
    J Natl Cancer Inst; 2001 Jun; 93(12):913-20. PubMed ID: 11416112
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dissemination risk index based on plasminogen activator system components in primary breast cancer.
    Bouchet C; Hacène K; Martin PM; Becette V; Tubiana-Hulin M; Lasry S; Oglobine J; Spyratos F
    J Clin Oncol; 1999 Oct; 17(10):3048-57. PubMed ID: 10506599
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantitative RT-PCR assays for the determination of urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 mRNA in primary tumor tissue of breast cancer patients: comparison to antigen quantification by ELISA.
    Biermann JC; Holzscheiter L; Kotzsch M; Luther T; Kiechle-Bahat M; Sweep FC; Span PN; Schmitt M; Magdolen V
    Int J Mol Med; 2008 Feb; 21(2):251-9. PubMed ID: 18204793
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor-biological factors uPA and PAI-1 as stratification criteria of a multicenter adjuvant chemotherapy trial in node-negative breast cancer.
    Prechtl A; Harbeck N; Thomssen C; Meisner C; Braun M; Untch M; Wieland M; Lisboa B; Cufer T; Graeff H; Selbmann K; Schmitt M; Jänicke F
    Int J Biol Markers; 2000; 15(1):73-8. PubMed ID: 10763145
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.